Information Provided By:
Fly News Breaks for May 19, 2016
CPXX
May 19, 2016 | 08:49 EDT
Roth Capital analyst Joseph Pantginis raised his price target for Celator Pharmaceuticals to $26 from $22 after the FDA awarded its Vyxeos the Breakthrough Therapy designation, which is an important step on the path to what the analyst believes is likely approval. Pantginis says the designation boosts his confidence that the potential launch timeline provided by the company of mid-2017 will be met or beat. He reiterates a Buy rating on the shares.
News For CPXX From the Last 2 Days
There are no results for your query CPXX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.